Insider Selling: Maze Therapeutics (NASDAQ:MAZE) Insider Sells $52,437.07 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Phillips Courtney sold 1,981 shares of Maze Therapeutics stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $26.47, for a total value of $52,437.07. Following the completion of the sale, the insider directly owned 9,019 shares in the company, valued at $238,732.93. This represents a 18.01% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Phillips Courtney also recently made the following trade(s):

• On Thursday, September 3rd, Phillips Courtney sold 2,012 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.01, for a total value of $52,332.12.

Maze Therapeutics Price Performance

Shares of Maze Therapeutics stock traded up $0.34 during trading on Friday, reaching $26.21. The company’s stock had a trading volume of 273,266 shares, compared to its average volume of 637,671. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. Maze Therapeutics, Inc. has a 12-month low of $14.27 and a 12-month high of $53.65. The company has a market capitalization of $1.46 billion, a P/E ratio of -10.40 and a beta of 2.17. The business has a 50 day moving average price of $28.74 and a 200-day moving average price of $31.20.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.76). As a group, sell-side analysts anticipate that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on MAZE. BTIG Research reiterated a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research note on Wednesday, August 12th. TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Finally, Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Three research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $66.00.

Institutional Trading of Maze Therapeutics

Large investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Maze Therapeutics during the 1st quarter worth about $57,000. Goldman Sachs Group Inc. purchased a new position in Maze Therapeutics in the 1st quarter valued at about $145,000. Rhumbline Advisers purchased a new position in Maze Therapeutics in the 1st quarter valued at about $80,000. Geode Capital Management LLC boosted its stake in shares of Maze Therapeutics by 8.8% during the 2nd quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock worth $2,838,000 after purchasing an additional 18,773 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Maze Therapeutics by 387.0% during the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after buying an additional 3,371 shares in the last quarter.

Key Headlines Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.